Thermo Fisher Scientific (TMO) Receives $220.08 Average PT from Analysts

Shares of Thermo Fisher Scientific (NYSE:TMO) have received a consensus rating of “Buy” from the eighteen analysts that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $220.08.

Several equities research analysts have recently weighed in on TMO shares. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “sell” rating to a “hold” rating in a research note on Saturday, January 20th. Evercore ISI started coverage on shares of Thermo Fisher Scientific in a research note on Wednesday, January 3rd. They set an “outperform” rating and a $220.00 target price for the company. Bank of America increased their target price on shares of Thermo Fisher Scientific from $235.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, February 1st. BTIG Research started coverage on shares of Thermo Fisher Scientific in a research note on Friday, January 5th. They set a “buy” rating and a $230.00 target price for the company. Finally, ValuEngine upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Friday, February 2nd.

How to Become a New Pot Stock Millionaire

NYSE TMO traded down $1.10 during trading hours on Thursday, hitting $215.89. The company had a trading volume of 1,377,917 shares, compared to its average volume of 1,296,395. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.34 and a quick ratio of 0.92. Thermo Fisher Scientific has a 1-year low of $154.59 and a 1-year high of $226.44. The company has a market capitalization of $86,741.15, a PE ratio of 22.75, a P/E/G ratio of 1.59 and a beta of 1.15.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, January 31st. The medical research company reported $2.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.66 by $0.13. Thermo Fisher Scientific had a net margin of 10.64% and a return on equity of 16.01%. The company had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $5.72 billion. During the same quarter in the prior year, the firm posted $2.41 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 22.1% on a year-over-year basis. research analysts expect that Thermo Fisher Scientific will post 10.84 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Monday, April 16th. Investors of record on Thursday, March 15th were issued a dividend of $0.17 per share. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. This represents a $0.68 annualized dividend and a yield of 0.31%. The ex-dividend date was Wednesday, March 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 7.17%.

In related news, CEO Marc N. Casper sold 40,000 shares of the stock in a transaction dated Thursday, March 22nd. The shares were sold at an average price of $210.16, for a total transaction of $8,406,400.00. Following the completion of the transaction, the chief executive officer now directly owns 334,622 shares of the company’s stock, valued at $70,324,159.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Gregory J. Herrema sold 33,327 shares of the stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $219.70, for a total transaction of $7,321,941.90. Following the transaction, the senior vice president now directly owns 60,471 shares of the company’s stock, valued at $13,285,478.70. The disclosure for this sale can be found here. Insiders have sold 88,827 shares of company stock valued at $19,012,672 over the last three months. 0.49% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Schroder Investment Management Group increased its holdings in Thermo Fisher Scientific by 28.1% in the fourth quarter. Schroder Investment Management Group now owns 1,103,685 shares of the medical research company’s stock valued at $209,568,000 after buying an additional 242,062 shares in the last quarter. Americafirst Capital Management LLC acquired a new stake in shares of Thermo Fisher Scientific in the third quarter valued at approximately $876,000. Rockland Trust Co. grew its position in shares of Thermo Fisher Scientific by 7.3% in the fourth quarter. Rockland Trust Co. now owns 62,332 shares of the medical research company’s stock valued at $11,836,000 after purchasing an additional 4,221 shares during the last quarter. Swiss National Bank grew its position in shares of Thermo Fisher Scientific by 2.2% in the fourth quarter. Swiss National Bank now owns 1,476,432 shares of the medical research company’s stock valued at $280,345,000 after purchasing an additional 31,800 shares during the last quarter. Finally, Honeywell International Inc. grew its position in shares of Thermo Fisher Scientific by 18.0% in the fourth quarter. Honeywell International Inc. now owns 230,000 shares of the medical research company’s stock valued at $43,672,000 after purchasing an additional 35,100 shares during the last quarter. 87.62% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This article was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.thelincolnianonline.com/2018/04/22/thermo-fisher-scientific-tmo-receives-220-08-average-pt-from-analysts.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply